Jane C. Weeks

32.6k total citations · 12 hit papers
252 papers, 24.9k citations indexed

About

Jane C. Weeks is a scholar working on Oncology, Public Health, Environmental and Occupational Health and Economics and Econometrics. According to data from OpenAlex, Jane C. Weeks has authored 252 papers receiving a total of 24.9k indexed citations (citations by other indexed papers that have themselves been cited), including 117 papers in Oncology, 83 papers in Public Health, Environmental and Occupational Health and 70 papers in Economics and Econometrics. Recurrent topics in Jane C. Weeks's work include Global Cancer Incidence and Screening (54 papers), Palliative Care and End-of-Life Issues (53 papers) and Health Systems, Economic Evaluations, Quality of Life (48 papers). Jane C. Weeks is often cited by papers focused on Global Cancer Incidence and Screening (54 papers), Palliative Care and End-of-Life Issues (53 papers) and Health Systems, Economic Evaluations, Quality of Life (48 papers). Jane C. Weeks collaborates with scholars based in United States, Canada and Netherlands. Jane C. Weeks's co-authors include Craig C. Earle, Jennifer W. Mack, John Z. Ayanian, Nancy L. Keating, Bridget A. Neville, Susan D. Block, Joanne Wolfe, Mary Beth Landrum, Holcombe E. Grier and Paul D. Cleary and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Jane C. Weeks

247 papers receiving 24.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Relationship Between Cancer Patients' Predictions of Prognosis and Their Treatment Preferences

1998 1.0k citations Jane C. Weeks profile →
Patients' Expectations about Effects of Chemotherapy for Advanced Cancer

2012 832 citations Jane C. Weeks, Angel M. Cronin et al. New England Journal of Medicine profile →
Symptoms and Suffering at the End of Life in Children with Cancer

2000 822 citations Jane C. Weeks et al. New England Journal of Medicine profile →
Trends in the Aggressiveness of Cancer Care Near the End of Life

2004 759 citations Craig C. Earle, Bridget A. Neville et al. Journal of Clinical Oncology profile →
Aggressiveness of Cancer Care Near the End of Life: Is It a Quality-of-Care Issue?

2008 727 citations Craig C. Earle, Mary Beth Landrum et al. Journal of Clinical Oncology profile →
Identifying Potential Indicators of the Quality of End-of-Life Cancer Care From Administrative Data

2003 693 citations Craig C. Earle, Jane C. Weeks et al. Journal of Clinical Oncology profile →
End-of-Life Discussions, Goal Attainment, and Distress at the End of Life: Predictors and Outcomes of Receipt of Care Consistent With Preferences

2010 632 citations Jane C. Weeks, Alexi A. Wright et al. Journal of Clinical Oncology profile →
Short-term Quality-of-Life Outcomes Following Laparoscopic-Assisted Colectomy vs Open Colectomy for Colon Cancer<SUBTITLE>A Randomized Trial</SUBTITLE>

2002 574 citations Jane C. Weeks profile →
Use of Alternative Medicine by Women with Early-Stage Breast Cancer

1999 504 citations Edward Guadagnoli, Jane C. Weeks et al. New England Journal of Medicine profile →
Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network

2012 475 citations Nancy U. Lin, Melissa E. Hughes et al. Cancer profile →
Associations Between End-of-Life Discussion Characteristics and Care Received Near Death: A Prospective Cohort Study

2012 418 citations Angel M. Cronin, Nancy L. Keating et al. Journal of Clinical Oncology profile →
Family Perspectives on Aggressive Cancer Care Near the End of Life

2016 328 citations Alexi A. Wright, Nancy L. Keating et al. profile →

Peers

Countries citing papers authored by Jane C. Weeks

Since Specialization

Citations

This map shows the geographic impact of Jane C. Weeks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jane C. Weeks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jane C. Weeks more than expected).

Fields of papers citing papers by Jane C. Weeks

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jane C. Weeks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jane C. Weeks. The network helps show where Jane C. Weeks may publish in the future.

Co-authorship network of co-authors of Jane C. Weeks

This figure shows the co-authorship network connecting the top 25 collaborators of Jane C. Weeks. A scholar is included among the top collaborators of Jane C. Weeks based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jane C. Weeks. Jane C. Weeks is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Does a multidisciplinary menopausal symptoms after cancer clinic reduce symptoms? 2021 ·Supportive Care in Cancer ·J. Hollingworth, (unknown), (unknown), (unknown), (unknown), (unknown), Jane C. Weeks, (unknown), Paul A. Cohen	3
2	Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer 2015 ·Obstetrical & Gynecological Survey ·Alexi A. Wright, Angel M. Cronin, Dana Milne, Michael A. Bookman, Robert A. Burger, David E. Cohn, Mihaela Cristea, Jennifer J. Griggs, Nancy L. Keating, Charles F. Levenback, Gina Mantia-Smaldone, Ursula A. Matulonis, Larissa A. Meyer, Joyce C. Niland, Jane C. Weeks, David M. O’Malley	5
3	Patient Beliefs About Palliative Radiation Therapy (RT) in Incurable Lung Cancer 2012 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), A. Cronin, Jane C. Weeks, Elizabeth A. Chrischilles, Jennifer L. Malin, James A. Hayman, Deborah Schrag	1
4	Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)‐positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network 2012 ·Cancer ·Rachel A. Freedman, Melissa E. Hughes, Rebecca A. Ottesen, Jane C. Weeks, Yulei He, Yu‐Ning Wong, Richard L. Theriault, Nancy L. Keating	60
5	Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study 2012 ·Breast Cancer Research ·Inês Vaz-Luís, Rebecca A. Ottesen, Melissa E. Hughes, P. Kelly Marcom, Beverly Moy, Hope S. Rugo, Richard L. Theriault, John L. Wilson, Joyce C. Niland, Jane C. Weeks, Nancy U. Lin	109
6	Comparative Effectiveness of Oxaliplatin vs Non–Oxaliplatin-containing Adjuvant Chemotherapy for Stage III Colon Cancer 2012 ·JNCI Journal of the National Cancer Institute ·Hanna K. Sanoff, William R. Carpenter, Christopher F. Martin, Daniel J. Sargent, Jeffrey A. Meyerhardt, Til Stürmer‎, Jason P. Fine, Jane C. Weeks, Joyce C. Niland, Katherine L. Kahn, Maria J. Schymura, Deborah Schrag	75
7	Relationship between reproductive history, anthropometrics, lifestyle factors, and the likelihood of persistent chemotherapy-related amenorrhea in women with premenopausal breast cancer 2011 ·Fertility and Sterility ·Mary E. Abusief, Stacey A. Missmer, Elizabeth S. Ginsburg, Jane C. Weeks, Ann H. Partridge	15
8	Continued Use of Trastuzumab Beyond Disease Progression in the National Comprehensive Cancer Network: Should We Practice Ahead of the Evidence? 2011 ·The Oncologist ·Yu‐Ning Wong, Rebecca A. Ottesen, Melissa E. Hughes, Joyce C. Niland, Richard L. Theriault, Stephen B. Edge, Douglas W. Blayney, Jane C. Weeks	7
9	Hospice Care and Survival among Elderly Patients with Lung Cancer 2011 ·Journal of Palliative Medicine ·Akiko Saito, Mary Beth Landrum, Bridget A. Neville, John Z. Ayanian, Jane C. Weeks, Craig C. Earle	88
10	Cost-Effectiveness of Computed Tomography Screening for Lung Cancer in the United States 2011 ·Journal of Thoracic Oncology ·Pamela M. McMahon, Chung Yin Kong, Colleen Bouzan, Milton C. Weinstein, Lauren E. Cipriano, Angela C. Tramontano, Bruce E. Johnson, Jane C. Weeks, G. Scott Gazelle	170
11	Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study 2011 ·BMC Cancer ·S. Yousuf Zafar, Jennifer L. Malin, Steven C. Grambow, David H. Abbott, Deborah Schrag, (unknown), Leah L. Zullig, Jane C. Weeks, Mona N. Fouad, John Z. Ayanian, Robert B. Wallace, Katherine L. Kahn, Peter Ganz, Paul Catalano, Dee W. West, Dawn Provenzale	8
12	Evaluating claims-based indicators of the intensity of end-of-life cancer care 2005 ·International Journal for Quality in Health Care ·Craig C. Earle, Bridget A. Neville, Mary Beth Landrum, (unknown), Jane C. Weeks, Susan D. Block, Eva Grunfeld, John Z. Ayanian	315
13	Factors influencing treatment recommendations in early-stage Hodgkin’s disease: a survey of physicians 2004 ·Annals of Oncology ·Andrea K. Ng, (unknown), Donna Neuberg, Barbara Silver, Jane C. Weeks, Peter Mauch	9
14	Communication Between Physicians and Older Women With Localized Breast Cancer: Implications for Treatment and Patient Satisfaction 2002 ·Journal of Clinical Oncology ·Wenchi Liang, Caroline B. Burnett, Julia H. Rowland, Neal J. Meropol, (unknown), Yi‐Ting Hwang, Rebecca A. Silliman, Jane C. Weeks, Jeanne S. Mandelblatt	86
15	Outcomes Research in Oncology: History, Conceptual Framework, and Trends in the Literature 2000 ·JNCI Journal of the National Cancer Institute ·Stephanie J. Lee, Craig C. Earle, Jane C. Weeks	68
16	Who Gets Chemotherapy for Metastatic Lung Cancer? 2000 ·CHEST Journal ·Craig C. Earle, Laura Venditti, Peter J. Neumann, Richard D. Gelber, Milton C. Weinstein, Arnold L. Potosky, Jane C. Weeks	198
17	Improving discussion of surgical treatment options for patients with breast cancer: local medical opinion leaders versus audit and performance feedback 2000 ·Breast Cancer Research and Treatment ·Edward Guadagnoli, Stephen B. Soumerai, Jerry H. Gurwitz, Catherine Borbas, Charles L. Shapiro, Jane C. Weeks, Nora Morris	35
18	Equine agitation behaviors. 1996 ·Equine practice ·Jane C. Weeks, Alan M. Beck	22
19	Comparison of Time-tradeoff Utilities and Rating Scale Values of Cancer Patients and Their Relatives 1995 ·Medical Decision Making ·(unknown), Diane L. Fairclough, (unknown), Jane C. Weeks	74
20	Cost Effectiveness of Prophylactic Intravenous Immune Globulin in Chronic Lymphocytic Leukemia 1991 ·New England Journal of Medicine ·Jane C. Weeks, Maureen Tierney, Milton C. Weinstein	157

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact